Avidity (RNA) Form 144: 30,914 PSU-Derived Shares Proposed for Sale

Rhea-AI Filing Summary

Form 144 summary for Avidity Biosciences (RNA): The filing notifies a proposed sale of 30,914 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $1,182,769.64, scheduled for 08/06/2025. The securities were acquired as Performance Stock Units from the issuer on 12/17/2024 (amount 30,914; date of payment listed as 12/17/2024; nature of payment: N/A). The filing reports "Nothing to Report" for securities sold in the past three months. Several filer identification and notice fields (CIK, submission contact name, date of notice) are blank or not provided in the document, limiting disclosure.

Positive

• Proposed sale routed through a registered broker: Morgan Stanley Smith Barney LLC is named as the broker for the sale on NASDAQ.
• Securities were acquired as Performance Stock Units from the issuer on 12/17/2024, as disclosed in the filing.
• No securities sold in the past three months is explicitly stated: "Nothing to Report".

Negative

• Key filer identification fields are blank or not provided (Filer CIK, filer contact name and details are missing in the document).
• Date of notice is not provided in the filing, limiting clarity on timing of the disclosure.
• Limited disclosure reduces transparency, constraining investor ability to assess the seller's identity and the sale's context.

Insights

Financial Analyst

TL;DR: Form 144 discloses a proposed insider sale of 30,914 shares (~$1.18M) with limited filer identification, constraining impact assessment.

The filing documents a planned sale of 30,914 common shares via Morgan Stanley Smith Barney LLC on NASDAQ dated 08/06/2025 and shows these shares were acquired as Performance Stock Units on 12/17/2024. The aggregate market value is explicitly stated as $1,182,769.64. The form does not disclose filer CIK, contact name, or the date of notice, which reduces transparency and makes it difficult to assess timing, insider identity, or the sale's relative significance to shareholders.

Corporate Governance Expert

TL;DR: PSU-derived shares are being offered for sale; missing filer and date fields weaken disclosure and investor transparency.

The notice confirms the securities were acquired from the issuer as Performance Stock Units on 12/17/2024 and that the broker handling the sale is Morgan Stanley Smith Barney LLC. The filing includes the required Rule 144 representation and indicates no sales in the prior three months. However, absent filer identification (CIK and submission contact) and an explicit date of notice, the document provides incomplete identification and timing context, which is a transparency concern under routine disclosure expectations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	30914	1182769.64	120538359	08/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/17/2024	Performance Stock Units	Issuer			30914	12/17/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Avidity Biosciences (RNA) disclose?

The filing discloses a proposed sale of 30,914 common shares on 08/06/2025 via Morgan Stanley Smith Barney LLC on NASDAQ with aggregate value $1,182,769.64.

When were the shares to be sold acquired for Avidity (RNA)?

The shares were acquired as Performance Stock Units from the issuer on 12/17/2024; amount acquired: 30,914; date of payment listed as 12/17/2024.

Does the Form 144 report any sales of Avidity (RNA) securities in the past three months?

No. The filing explicitly states "Nothing to Report" for securities sold during the past three months.

Who is the broker listed for the proposed sale in the Avidity (RNA) filing?

The broker is listed as Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Are filer identity and notice date provided in this Form 144 for RNA?

No. The document shows blank or missing entries for filer CIK, submission contact name, and the date of notice.